These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26940442)

  • 1. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
    Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
    Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
    Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
    Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
    Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
    Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
    Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
    Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
    Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
    Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
    J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of
    Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
    Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
    J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
    George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
    Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem high-dose 131I-MIBG therapy supported by dosimetry in pediatric patients with relapsed-refractory high-risk neuroblastoma: the Bambino Gesu' Children's Hospital experience.
    Altini C; Villani MF; Di Giannatale A; Cassano B; Pizzoferro M; Serra A; Castellano A; Cannatà V; Garganese MC
    Nucl Med Commun; 2022 Feb; 43(2):129-144. PubMed ID: 34720106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures.
    Evans AC; Setzkorn T; Edmondson DA; Segelke H; Wilson PF; Matthay KK; Granger MM; Marachelian A; Haas-Kogan DA; DuBois SG; Coleman MA
    Radiat Res; 2022 Feb; 197(2):101-112. PubMed ID: 34673986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation exposure in nurses during care of
    Taniguchi Y; Wakabayashi H; Inaki A; Kayano D; Yamada M; Kinuya S
    Ann Nucl Med; 2020 Jun; 34(6):441-447. PubMed ID: 32297135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
    Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
    J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma
    Chimeno JM; Sebastià N; Torres-Espallardo I; Balaguer J; Candela-Juan C; Loaiza JL; Adria M; Ibanez-Rosello B; Cañete A; Martí-Bonmatí L; Montoro A
    Int J Radiat Biol; 2019 Mar; 95(3):314-320. PubMed ID: 30496023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
    Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
    Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.
    Shusterman S; Grant FD; Lorenzen W; Davis RT; Laffin S; Drubach LA; Fahey FH; Treves ST
    Semin Nucl Med; 2011 Sep; 41(5):354-63. PubMed ID: 21803185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
    Flower MA; Fielding SL
    Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.